Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients

Giuseppe Derosa, Pamela Maffioli, Ilaria Ferrari, Angela D'Angelo, Elena Fogari, Ilaria Palumbo, Sabrina Randazzo, Arrigo F G Cicero

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Our study wants to evaluate the effects of one year treatment with orlistat plus L-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and insulin resistance state in type 2 diabetic patients. Two hundred and fifty-eight patients with uncontrolled type 2 diabetes mellitus (T2DM) [glycated hemoglobin (HbA1c) > 8.0%] in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take orlistat 120 mg three times a day plus L-carnitine 2 g one time a day or orlistat 120 mg three times a day. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), retinol binding protein-4 (RBP-4), resistin, visfatin, high sensitivity-C reactive protein (Hs-CRP). We observed a faster, and better decrease of body weight, HbA1c, FPG, PPG, LDL-C, HOMA-IR with orlistat plus L-carnitine compared to orlistat. A faster improvement of TC, Tg, FPI, resistin, RBP-4, visfatin, and Hs-CRP was reached with orlistat plus L-carnitine compared to orlistat. We can safely conclude that the association of orlistat plus L-carnitine was better than orlistat in improving body weight, glycemic and lipid profile, insulin resistance, and inflammatory parameters and no significant adverse events were recorded.

Original languageEnglish
Pages (from-to)777-786
Number of pages10
JournalEndocrine Journal
Volume57
Issue number9
DOIs
Publication statusPublished - 2010

Fingerprint

Carnitine
Insulin Resistance
Fasting
Body Weight
Nicotinamide Phosphoribosyltransferase
Resistin
Glucose
Retinol-Binding Proteins
Insulin
C-Reactive Protein
LDL Cholesterol
Triglycerides
Homeostasis
Cholesterol
orlistat
Lipids
Glycosylated Hemoglobin A
Hypoglycemic Agents
Type 2 Diabetes Mellitus
HDL Cholesterol

Keywords

  • HOMA-IR
  • Insulin resistance
  • L-carnitine
  • Orlistat
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. / Derosa, Giuseppe; Maffioli, Pamela; Ferrari, Ilaria; D'Angelo, Angela; Fogari, Elena; Palumbo, Ilaria; Randazzo, Sabrina; Cicero, Arrigo F G.

In: Endocrine Journal, Vol. 57, No. 9, 2010, p. 777-786.

Research output: Contribution to journalArticle

@article{4e5e4b65fc3c446d920028a37a4797f3,
title = "Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients",
abstract = "Our study wants to evaluate the effects of one year treatment with orlistat plus L-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and insulin resistance state in type 2 diabetic patients. Two hundred and fifty-eight patients with uncontrolled type 2 diabetes mellitus (T2DM) [glycated hemoglobin (HbA1c) > 8.0{\%}] in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take orlistat 120 mg three times a day plus L-carnitine 2 g one time a day or orlistat 120 mg three times a day. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), retinol binding protein-4 (RBP-4), resistin, visfatin, high sensitivity-C reactive protein (Hs-CRP). We observed a faster, and better decrease of body weight, HbA1c, FPG, PPG, LDL-C, HOMA-IR with orlistat plus L-carnitine compared to orlistat. A faster improvement of TC, Tg, FPI, resistin, RBP-4, visfatin, and Hs-CRP was reached with orlistat plus L-carnitine compared to orlistat. We can safely conclude that the association of orlistat plus L-carnitine was better than orlistat in improving body weight, glycemic and lipid profile, insulin resistance, and inflammatory parameters and no significant adverse events were recorded.",
keywords = "HOMA-IR, Insulin resistance, L-carnitine, Orlistat, Type 2 diabetes",
author = "Giuseppe Derosa and Pamela Maffioli and Ilaria Ferrari and Angela D'Angelo and Elena Fogari and Ilaria Palumbo and Sabrina Randazzo and Cicero, {Arrigo F G}",
year = "2010",
doi = "10.1507/endocrj.K10E-049",
language = "English",
volume = "57",
pages = "777--786",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients

AU - Derosa, Giuseppe

AU - Maffioli, Pamela

AU - Ferrari, Ilaria

AU - D'Angelo, Angela

AU - Fogari, Elena

AU - Palumbo, Ilaria

AU - Randazzo, Sabrina

AU - Cicero, Arrigo F G

PY - 2010

Y1 - 2010

N2 - Our study wants to evaluate the effects of one year treatment with orlistat plus L-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and insulin resistance state in type 2 diabetic patients. Two hundred and fifty-eight patients with uncontrolled type 2 diabetes mellitus (T2DM) [glycated hemoglobin (HbA1c) > 8.0%] in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take orlistat 120 mg three times a day plus L-carnitine 2 g one time a day or orlistat 120 mg three times a day. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), retinol binding protein-4 (RBP-4), resistin, visfatin, high sensitivity-C reactive protein (Hs-CRP). We observed a faster, and better decrease of body weight, HbA1c, FPG, PPG, LDL-C, HOMA-IR with orlistat plus L-carnitine compared to orlistat. A faster improvement of TC, Tg, FPI, resistin, RBP-4, visfatin, and Hs-CRP was reached with orlistat plus L-carnitine compared to orlistat. We can safely conclude that the association of orlistat plus L-carnitine was better than orlistat in improving body weight, glycemic and lipid profile, insulin resistance, and inflammatory parameters and no significant adverse events were recorded.

AB - Our study wants to evaluate the effects of one year treatment with orlistat plus L-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and insulin resistance state in type 2 diabetic patients. Two hundred and fifty-eight patients with uncontrolled type 2 diabetes mellitus (T2DM) [glycated hemoglobin (HbA1c) > 8.0%] in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take orlistat 120 mg three times a day plus L-carnitine 2 g one time a day or orlistat 120 mg three times a day. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), retinol binding protein-4 (RBP-4), resistin, visfatin, high sensitivity-C reactive protein (Hs-CRP). We observed a faster, and better decrease of body weight, HbA1c, FPG, PPG, LDL-C, HOMA-IR with orlistat plus L-carnitine compared to orlistat. A faster improvement of TC, Tg, FPI, resistin, RBP-4, visfatin, and Hs-CRP was reached with orlistat plus L-carnitine compared to orlistat. We can safely conclude that the association of orlistat plus L-carnitine was better than orlistat in improving body weight, glycemic and lipid profile, insulin resistance, and inflammatory parameters and no significant adverse events were recorded.

KW - HOMA-IR

KW - Insulin resistance

KW - L-carnitine

KW - Orlistat

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=77957733692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957733692&partnerID=8YFLogxK

U2 - 10.1507/endocrj.K10E-049

DO - 10.1507/endocrj.K10E-049

M3 - Article

VL - 57

SP - 777

EP - 786

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 9

ER -